

Total Synthesis of (+)-Asperlin

Subban Ramesh and Richard W. Franck*


Department of Chemistry, Hunter College/CUNY,

695 Park Ave., New York, NY 10021

(Received 22 December 1989)

Abstract: A stereochemically unambiguous synthesis of (+)-asperlin from L-rhamnose establishes the configuration of the antibiotic as 4*S*, 5*S*, 6*S*, 7*R*.

Asperlin (1), a crystalline metabolite from *Aspergillus nidulans*, has been shown to exhibit antitumor and antibacterial activity. The gross structure of 1 was assigned by Argoudelis in 1966,¹ and early synthetic studies by Perlin demonstrated that the C-4 and C-5 substituents of the lactone ring had the L-threo configuration. Perlin also proved the *trans* stereochemistry of the epoxypropyl sidechain.² However the absolute stereochemistry of the sidechain of this deceptively simple molecule has eluded a definitive assignment. Thus, NMR studies^{3a} were used to propose the absolute stereochemistry of the sidechain epoxide as 6*R*,7*S*, an assignment that contradicted the X-ray analysis which assigned the 6*S*,7*R* configuration.^{3b} Rabanal^{4a} and, very recently, Shing^{4b} have synthesized unnatural diastereomers of asperlin and deduced the absolute stereochemistry by exclusion. In fact, there has been only one synthesis of (+)-asperlin reported in the literature⁵; and the method used to prepare the epoxide did not establish its absolute configuration. In this communication, we wish to report an enantiospecific synthesis of 1 which furnishes incontrovertible evidence for its absolute stereochemistry as 4*S*, 5*S*, 6*S*, 7*R*. We chose to use a sugar precursor that had the requisite stereochemistry at the future C-4 and C-6, that combined with unambiguous chemical transformations, leaves no doubt about C-5 and C-7. As illustrated in the retrosynthesis scheme 1, we envisioned the epoxide as arising from 2 and an intramolecular Horner-Wadsworth-Emmons reaction producing the lactone. The appropriate precursor for 3 was L-rhamnose, since it is readily available and needs an inversion only at C-3.




L-Rhamnose was converted to methyl rhamnoside using Binkley's procedure.⁶ The maneuver that left the C-3 OH free and blocked the C-2 and C-4 OH's was performed as follows. The C-2 and C-3 OH's were protected as an orthoacetate and the C-4 OH was silylated with TBDMSOTf to afford 6 (Scheme 2). The crude silyl ether-orthoacetate was hydrolyzed with 90% aqueous CH_3COOH , following well-established precedents for the regioselective ring opening of axial-equatorial orthoesters.⁷ We thus obtained 7 in 52% overall yield from methyl rhamnoside. With the C-3 OH unblocked, its inversion was the next problem to be solved. Although Mitsunobu conditions were unsuccessful in our hands, the transformation was accomplished cleanly in two steps: PCC-MS oxidation⁸ of the alcohol 7 gave the ketone 8 which was stereoselectively reduced to the axial alcohol 9 in 94% overall yield.⁹ The alcohol was esterified to give the phosphonate 10 in 95% yield.¹⁰ Conventional methods (e.g. aqueous acid) when employed to hydrolyze the methyl glycoside led to deblocking of TBDMS and/or phosphonate groups. The hydrolysis was efficiently done in two steps: (i) the methyl glycoside was converted to the 1-chloro sugar 11 by reacting it with BCl_3 in CH_2Cl_2 at -78°C and (ii) the 1-chloro sugar was reacted with Ag_2CO_3 in aqueous acetone to give 3 in 73% overall yield. The stage was set for the intramolecular HWE reaction. Several bases and reaction conditions were tried¹² but NaH/THF at room temperature gave satisfactory results to produce the lactone 12 in 32% yield. The lactone was converted to (+)-asperlin as follows: the remaining free OH was converted to its mesylate; then reaction of the mesylate with $n\text{-Bu}_4\text{NF}\cdot 3\text{H}_2\text{O}$ in CH_2Cl_2 at room temperature¹³ produced asperlin in 22% yield¹⁴. This material was identical to a sample of the natural product in all respects.¹⁵ Synthetic (+)-Asperlin: mp = $68\text{--}70^\circ$, $[\alpha]_D^{25} = +322^\circ$ (c = 0.2, 95% EtOH); lit. mp $71\text{--}73^\circ$, $[\alpha]_D^{25} = +345^\circ$ (c = 0.9, 95% EtOH); $^1\text{H NMR}$ (CDCl_3 , 300MHz) δ 7.11 (dd, 1H, J = 5.78, 9.77, H3), 6.26 (d, 1H, J = 9.74, H2), 5.35 (dd, 1H, J = 5.73, 2.82, H4), 4.14 (dd, 1H, J = 6.95, 2.81, H5), 3.14-3.09 (m, 2H, H6, H7), 2.18 (s, 3H, OAc), 1.43 (d, 3H, J = 5.04, CH_3); $^{13}\text{C NMR}$ (CDCl_3 , 75MHz) δ 169.8 (COCH_3); 161.5 (C1); 140.5 (C3); 124.9 (C2); 78.9 (C4); 62.1 (C5); 54.9 (C6); 54.6 (C7); 20.6 (CH_3CO); 17.0 (C8). Thus, we have achieved a total synthesis of (+)-asperlin which unambiguously establishes the absolute stereochemistry of the epoxide as drawn in 1.

Acknowledgement This research was supported by NIH grant CA 37359 and PSC/CUNY research grant program.

References and Notes

- (a) A.D. Argoudelis, J.H. Coats and R.R. Herr, *Antimicrob. Agents and Chemother.*, 1965, 801; S.P. Owen and B.K. Bhuyan, *ibid*; 1965, 804. (b) A.D. Argoudelis and J.F. Zieserl, *Tetrahedron Lett.* 1966, 7, 1969.
- S. Lesage and A.S. Perlin, *Can. J. Chem.*, 1978, 56, 2889; *Idem. ibid*; 1978, 56, 3117. These early workers used a numbering system where the lactone carbonyl was designated as C-1.
- (a) P. Dais and A.S. Perlin, *Can. J. Chem.*, 1985, 63, 1009. (b) K. Fukuyama, Y. Katsube, A. Noda, T. Mamasaki and Y. Hatsuda, *Bull. Chem. Soc. Jpn.*, 1978, 51, 3175.
- (a) S. Valverde, B. Herradon, R.M. Rabanal and M. Martin-Lomas, *Can. J. Chem.*, 1987, 65, 339.

Scheme 2



- (a) MeOH, Dowex-H⁺, heat (b) (EtO)₃CCH₃, DMF, cat. p-TosH, heat
 (c) TBDMSOTf, 2, 6-lutidine, CH₂Cl₂, 0°C (d) aq. acetic acid (90%)
 (e) PCC-MS, 3A^o MS, NaOAc, CH₂Cl₂, RT (f) NaBH₄ / MeOH, -78 °C
 (g) (EtO)₂POCH₂CO₂H, DCC, CH₂Cl₂, RT (h) BCl₃, CH₂Cl₂, -78 °C
 (i) Ag₂CO₃, aq. acetone, RT (j) NaH / THF, RT
 (k) MsCl, Et₃N, 0° to RT (l) Bu₄NF. 3H₂O, CH₂Cl₂, RT

- 4.(b) T.K.M. Shing and M. Aloui, *J. Chem.Soc., Chem. Commun.* 1988, 1525.
5. T. Murayama, T. Sugiyama and K. Yamashita, *Agric. Biol. Chem.*, 1987, 51, 2055. For a racemic synthesis see: H. Hiraoka, K. Furuta, N. Ikeda and H. Yamamoto, *Bull. Chem. Soc. Jpn.*, 1984, 57, 2777.
6. R.W. Binkley, G.S. Goewey and J.C. Johnston, *J. Org. Chem.*, 1984, 49, 992.
- 7.(a) J.F. King and A.D. Allbrett, *Can. J. Chem.*, 1970, 48, 1756 and references cited therein; (b) S. Hanessian and E. Moralioglu, *ibid.*, 1972, 50, 233.
8. J. Herscovici and K. Antonakis, *J. Chem. Soc., Chem. Commun.*, 1980, 561; J. Herscovici, M.J. Egron and K. Antonakis, *J. Chem. Soc., Perkin Trans I*, 1982, 1967.
9. O. Han and H. W. Liu, *Tetrahedron Lett.*, 1987, 28, 1073.
10. A. Hassner and V. Alexanian, *Tetrahedron Lett.*, 1978, 19, 4475; B. Neises and W. Steglich, *Angew. Chem. Int. Ed. Eng.*, 1978, 17, 522.
11. G. R. Perdomo and J.J. Krepinsky, *Tetrahedron Lett.*, 1987, 28, 5595. We have independently shown that BCl₃ in CH₂Cl₂ at -78°C converts methyl glycosides to 1-chloro sugars and that -OAc, -TBDMS and phosphonates are stable under these conditions.
- 12.(a) S.F. Donovan, M.A. Avery and J.E. McMurry, *Tetrahedron Lett.*, 1979, 20, 3287; (b) M.A. Blanchette, W. Choy, J.T., Davis, A.P. Essinfeld, S. Masamune, W.R. Roush and T. Sakai, *Tetrahedron Lett.*, 1984, 25, 2183. Other bases used: KOtBu/ THF; KHMDS/THF; NaHMDS/THF; LDA/THF.
13. J. Kuwajima, T. Murojushi and E. Nakamira, *Synthesis*, 1972, 602; J. Mayami, N. Uno and A. Kaji, *ibid.*, 1968, 1385.
- 14.(+)-Asperlin is not particularly stable to Bu₄NF. Thus, no other characterizable epoxy lactone could be detected in, or isolated from the reaction mixture.
15. All numbered compounds except for 6 and 11 were purified by chromatography to homogeneity and every compound gave ¹H and ¹³C NMR consistent with the assigned structure. For 10: [α]_D²⁵ = -51.9° (c = 2.72, CH₂Cl₂), ¹H NMR (CDCl₃, 300MHz) δ 4.97 (t, J_{2,3} and J_{3,4} = 3 Hz, H3); 4.80 (d, J = 3, H2); 4.42 (bs, H1); 4.1 (m, CH₂OP); 3.96 (m, H5); 3.58 (dd, J_{4,5} = 9, J_{3,4} = 3, H4); 3.27 (s, OMe); 2.91 (ABq with added coupling to P, CH₂-P); 2.01 (s, CH₃CO); 1.25 (t, CH₃); 1.15 (d, CH₃); 0.77 (s, t-Bu); 0.00 (s, MeSi); -0.2 (s, MeSi); ¹³C NMR (CDCl₃, 75MHz) δ 169.1 (COCH₃); 165.0 (COCH₂P); 98.1 (C1); 70.8, 69.9, 69.6 (C2,C3,C5); 64.4 (C2); 62.5,62.6 (CH₂OP); 55.1 (OMe); 33.9 (d, J=135, CH₂P); 25.5 (Me of t-Bu); 20.8 (CH₃CO); 17.8 (qC of t-Bu); 17.7 (C6); 16.3,16.2 (CH₂CH₂OP); -4.6,-4.9 (MeSi). M/e calcd. for C₂₁H₄₁O₆PSi: 512; Found (CI-methane) M+1 513. For 12: [α]_D²⁵ = +112.8° (c = 1.95, CH₂Cl₂), ¹H NMR (CDCl₃, 300MHz) δ 7.27 (dd, J=9.6,6.0, H3); 6.19 (d, J=9.6, H2); 5.15 (dd, J= 6.0,1.9, H4); 4.41 (dd, J= 8.8,1.9, H5); 4.20 (m, H7); 4.18 (dd, J= 8.8, 2.2, H6); 2.12 (s, CH₃CO); 1.29 (d, CH₃CH); 0.93 (s, t-Bu); 0.21,0.09 (MeSi); ¹³C NMR (CDCl₃, 75MHz) δ 169.9 (COCH₃); 162.2 (CO-lactone); 141.5, 124.6 (C=C); 78.1, 72.6, 68.2, 62.4 (C4-C7); 25.7 (Me of t-Bu); 20.8 (CH₃CO); 18.3 (qC of t-Bu); 16.8 (C8); -4.2,-5.1 (MeSi). M/e Calcd. for C₁₆H₂₈O₆Si: 344; Found (CI-methane) M+1 345.